Table 3.
Multivariable‐Adjusted HRs for Homoarginine for Major Adverse Events
| Modela | HR [95% CI] | Events (n) |
|---|---|---|
| All participants | ||
| 1 (n=1649) | 0.77 [0.60–0.98] | 60 |
| 2 (n=1471) | 0.75 [0.58–0.97] | 56 |
| 3 (n=1471) | 0.74 [0.57–0.96] | 56 |
| Acute coronary syndrome | ||
| 1 (n=589) | 0.61 [0.46–0.82] | 43 |
| 2 (n=533) | 0.66 [0.50–0.88] | 41 |
| 3 (n=533) | 0.65 [0.49–0.88] | 41 |
Data are presented for 1‐SD increase in log‐homoarginine (0.37). CABG indicates coronary artery bypass grafting; EPV, event per variable; HR, hazard ratio; PCI, percutaneous coronary intervention.
a
Model 1 adjusted for age and sex; model 2 adjusted for variables in model 1 plus body mass index, current smoking, diabetes mellitus, hypertension, and hyperlipidemia; model 3 adjusted for variables in model 2 plus in hospital treatment (PCI or CABG).